In human cells, VPAC1 was constitutively expressed in resting T cells and monocytes, with higher levels in monocytes and CD4+ T cells than in CD8+ T cells.
In plain wordsIn lab tests on human immune cells, the VIP receptor VPAC1 was present in resting cells, most in monocytes and CD4+ T cells.
- Outcome
- Not applicableVPAC1 expression in resting T cells and monocytes
- Study
humann: not reported in source
Purified human CD4+ and CD8+ T cells and monocytes- Outcome group
- Receptor activity and mechanism · Immune and inflammation
Source sentences
Using the novel fluorometric-based kinetic (real-time) RT-PCR, we determined that VPAC1 is constitutively expressed in resting T cells and monocytes; the levels of expression were significantly higher in monocytes and CD4(+) T cells than in CD8(+) T cells.
1 context sentence(design, population, supporting numbers)
Purified human peripheral blood CD4(+) T cells and CD8(+) T cells were stimulated via the TCR/CD3 receptor complex.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).